Matches in SemOpenAlex for { <https://semopenalex.org/work/W2006179225> ?p ?o ?g. }
- W2006179225 endingPage "840" @default.
- W2006179225 startingPage "826" @default.
- W2006179225 abstract "Death ligands, including TNF-α, CD95L/FasL, and TRAIL, mediate safeguard mechanisms against tumor growth and critically contribute to lymphocyte homeostasis. We investigated death receptor-mediated apoptosis and CD30/CD95 crosstalk in four CD30-positive cell lines of cutaneous anaplastic large-cell lymphoma (cALCL). Whereas CD95 stimulation strongly induced apoptosis in cALCL cells, the pro-apoptotic pathways of TNF-α and TRAIL were completely blocked at an early step. Expression of TNF receptor 1 was lost in three of four cell lines, providing an explanation for TNF-α unresponsiveness. TRAIL resistance may be explained by the consistent overexpression of cellular flice inhibitory protein (c-FLIP) (four of four cell lines) and frequent loss of the pro-apoptotic Bcl-2 protein Bid (three of four cell lines). Changes at the receptor-expression level were largely ruled out. CD30/CD95 crosstalk experiments showed that CD30 ligation leads to NF-κB-mediated c-FLIP upregulation in cALCL cells, which in turn conferred enhanced resistance to CD95-mediated apoptosis. Knockdown of c-FLIP by a lentiviral approach enhanced basic apoptosis rates in cALCL cells and diminished the CD30-mediated suppression of apoptosis, thus proving the significance of c-FLIP in this context. These in vitro findings may be indicative of the clinical situation of cALCL. Further clarifying the defects in apoptosis pathways in cutaneous lymphomas may lead to improved therapies for these disorders. Death ligands, including TNF-α, CD95L/FasL, and TRAIL, mediate safeguard mechanisms against tumor growth and critically contribute to lymphocyte homeostasis. We investigated death receptor-mediated apoptosis and CD30/CD95 crosstalk in four CD30-positive cell lines of cutaneous anaplastic large-cell lymphoma (cALCL). Whereas CD95 stimulation strongly induced apoptosis in cALCL cells, the pro-apoptotic pathways of TNF-α and TRAIL were completely blocked at an early step. Expression of TNF receptor 1 was lost in three of four cell lines, providing an explanation for TNF-α unresponsiveness. TRAIL resistance may be explained by the consistent overexpression of cellular flice inhibitory protein (c-FLIP) (four of four cell lines) and frequent loss of the pro-apoptotic Bcl-2 protein Bid (three of four cell lines). Changes at the receptor-expression level were largely ruled out. CD30/CD95 crosstalk experiments showed that CD30 ligation leads to NF-κB-mediated c-FLIP upregulation in cALCL cells, which in turn conferred enhanced resistance to CD95-mediated apoptosis. Knockdown of c-FLIP by a lentiviral approach enhanced basic apoptosis rates in cALCL cells and diminished the CD30-mediated suppression of apoptosis, thus proving the significance of c-FLIP in this context. These in vitro findings may be indicative of the clinical situation of cALCL. Further clarifying the defects in apoptosis pathways in cutaneous lymphomas may lead to improved therapies for these disorders. antibody cutaneous anaplastic large-cell lymphoma cellular flice inhibitory protein cellular inhibitor of apoptosis protein cutaneous T-cell lymphoma death-inducing signaling complex inhibitor of apoptosis protein lactate dehydrogenase lymphomatoid papulosis mycosis fungoides phosphate-buffered saline propidium iodide reverse transcription PCR Sézary syndrome TNF receptor TNFR-associated factor" @default.
- W2006179225 created "2016-06-24" @default.
- W2006179225 creator A5014442576 @default.
- W2006179225 creator A5018780132 @default.
- W2006179225 creator A5028359701 @default.
- W2006179225 creator A5029406176 @default.
- W2006179225 creator A5053886716 @default.
- W2006179225 creator A5063437249 @default.
- W2006179225 creator A5068741789 @default.
- W2006179225 creator A5081075130 @default.
- W2006179225 date "2010-03-01" @default.
- W2006179225 modified "2023-10-01" @default.
- W2006179225 title "Resistance of Cutaneous Anaplastic Large-Cell Lymphoma Cells to Apoptosis by Death Ligands Is Enhanced by CD30-Mediated Overexpression of c-FLIP" @default.
- W2006179225 cites W1491380704 @default.
- W2006179225 cites W1965650825 @default.
- W2006179225 cites W1969324239 @default.
- W2006179225 cites W1971620485 @default.
- W2006179225 cites W1983330474 @default.
- W2006179225 cites W1986222655 @default.
- W2006179225 cites W1992328442 @default.
- W2006179225 cites W1995410420 @default.
- W2006179225 cites W1998422493 @default.
- W2006179225 cites W2002370955 @default.
- W2006179225 cites W2005483847 @default.
- W2006179225 cites W2006122340 @default.
- W2006179225 cites W2013888495 @default.
- W2006179225 cites W2014631176 @default.
- W2006179225 cites W2017558550 @default.
- W2006179225 cites W2019490105 @default.
- W2006179225 cites W2021518638 @default.
- W2006179225 cites W2021581111 @default.
- W2006179225 cites W2022033793 @default.
- W2006179225 cites W2027303416 @default.
- W2006179225 cites W2028866476 @default.
- W2006179225 cites W2032860349 @default.
- W2006179225 cites W2037614257 @default.
- W2006179225 cites W2043978197 @default.
- W2006179225 cites W2049496286 @default.
- W2006179225 cites W2060137381 @default.
- W2006179225 cites W2062853648 @default.
- W2006179225 cites W2063936572 @default.
- W2006179225 cites W2066053147 @default.
- W2006179225 cites W2068751711 @default.
- W2006179225 cites W2076542620 @default.
- W2006179225 cites W2079523831 @default.
- W2006179225 cites W2086484481 @default.
- W2006179225 cites W2091511314 @default.
- W2006179225 cites W2093448823 @default.
- W2006179225 cites W2096160655 @default.
- W2006179225 cites W2099664441 @default.
- W2006179225 cites W2101722758 @default.
- W2006179225 cites W2104024292 @default.
- W2006179225 cites W2105555467 @default.
- W2006179225 cites W2111034566 @default.
- W2006179225 cites W2117118862 @default.
- W2006179225 cites W2122541507 @default.
- W2006179225 cites W2124489451 @default.
- W2006179225 cites W2128497497 @default.
- W2006179225 cites W2131934858 @default.
- W2006179225 cites W2146907762 @default.
- W2006179225 cites W2148778964 @default.
- W2006179225 cites W2154475699 @default.
- W2006179225 cites W2161214047 @default.
- W2006179225 cites W2165441215 @default.
- W2006179225 cites W2315613727 @default.
- W2006179225 cites W2396056147 @default.
- W2006179225 doi "https://doi.org/10.1038/jid.2009.299" @default.
- W2006179225 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19890350" @default.
- W2006179225 hasPublicationYear "2010" @default.
- W2006179225 type Work @default.
- W2006179225 sameAs 2006179225 @default.
- W2006179225 citedByCount "24" @default.
- W2006179225 countsByYear W20061792252012 @default.
- W2006179225 countsByYear W20061792252013 @default.
- W2006179225 countsByYear W20061792252014 @default.
- W2006179225 countsByYear W20061792252015 @default.
- W2006179225 countsByYear W20061792252016 @default.
- W2006179225 countsByYear W20061792252017 @default.
- W2006179225 countsByYear W20061792252018 @default.
- W2006179225 countsByYear W20061792252019 @default.
- W2006179225 countsByYear W20061792252020 @default.
- W2006179225 crossrefType "journal-article" @default.
- W2006179225 hasAuthorship W2006179225A5014442576 @default.
- W2006179225 hasAuthorship W2006179225A5018780132 @default.
- W2006179225 hasAuthorship W2006179225A5028359701 @default.
- W2006179225 hasAuthorship W2006179225A5029406176 @default.
- W2006179225 hasAuthorship W2006179225A5053886716 @default.
- W2006179225 hasAuthorship W2006179225A5063437249 @default.
- W2006179225 hasAuthorship W2006179225A5068741789 @default.
- W2006179225 hasAuthorship W2006179225A5081075130 @default.
- W2006179225 hasBestOaLocation W20061792251 @default.
- W2006179225 hasConcept C120665830 @default.
- W2006179225 hasConcept C121332964 @default.
- W2006179225 hasConcept C169822122 @default.
- W2006179225 hasConcept C179464577 @default.
- W2006179225 hasConcept C17991360 @default.
- W2006179225 hasConcept C190283241 @default.
- W2006179225 hasConcept C203014093 @default.